Related Experiment Video
Updated: Apr 12, 2026
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
[Second-line chemotherapy for advanced pancreatic cancer]
Atsushi Sato1, Kensuke Saito, Takenori Takahata
1Dept. of Medical Oncology, Hirosaki University Graduate School of Medicine.
Abstract:
Many investigators have attempted to reach a consensus, though with limited evidence available, on second-line chemotherapy for advanced pancreatic cancer. Specifically, treatment consists of gemcitabine-based regimens and 5-FU-based regimens. The regimen that is not used for first-line chemotherapy will be used as second-line chemotherapy. In Japan, S-1 is frequently used in 5-FU-based regimens. When the FOLFIRINOX regimen is used as first-line chemotherapy, gemcitabine is recommended as second-line chemotherapy. On the other hand, when nab-PTX/gemcitabine is used as first-line chemotherapy, S-1 is recommended as second-line chemotherapy.
More Related Videos
12:07Laparoscopic Radical Antegrade Modular Pancreatosplenectomy via Dorsal-Caudal Artery Approach for Pancreatic Neck-Body Cancer
Published on: November 18, 2022
08:12Laparoscopic Pancreatoduodenectomy for Pancreatic Cancer Using In-Situ No-Touch Isolation Technique
Published on: February 2, 2022
